See more : Aegean Airlines S.A. (AGZNF) Income Statement Analysis – Financial Results
Complete financial analysis of Molecular Partners AG (MLLCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Molecular Partners AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Milton Capital Plc (MII.L) Income Statement Analysis – Financial Results
- Fox Corporation (FOXA) Income Statement Analysis – Financial Results
- Gas Arabian Services Company (9528.SR) Income Statement Analysis – Financial Results
- Polymetal International plc (POLY.L) Income Statement Analysis – Financial Results
- Schultze Special Purpose Acquisition Corp. II (SAMAU) Income Statement Analysis – Financial Results
Molecular Partners AG (MLLCF)
About Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.04M | 189.56M | 9.33M | 9.34M | 20.38M | 10.36M | 20.02M | 23.04M | 29.12M | 26.63M | 32.42M |
| Cost of Revenue | 47.84M | 49.90M | 54.96M | 56.08M | 43.50M | 15.60M | 17.82M | 14.57M | 1.17M | 170.75K | 1.22M |
| Gross Profit | -40.81M | 139.66M | -45.63M | -46.73M | -23.12M | -5.25M | 2.19M | 8.47M | 27.95M | 26.45M | 31.20M |
| Gross Profit Ratio | -579.80% | 73.68% | -489.07% | -500.12% | -113.40% | -50.67% | 10.96% | 36.76% | 96.00% | 99.36% | 96.23% |
| Research & Development | 48.78M | 50.75M | 55.72M | 56.08M | 43.50M | 38.20M | 37.45M | 35.19M | 23.92M | 18.79M | 20.82M |
| General & Administrative | 19.00M | 21.82M | 16.91M | 11.03M | 13.16M | 9.46M | 8.28M | 7.24M | 6.22M | 4.90M | 3.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 57.00K | 5.23M | 3.54M | 0.00 | 0.00 | 0.00 | 0.00 | 84.54K |
| SG&A | 19.00M | 21.82M | 16.91M | 11.03M | 13.16M | 9.46M | 8.28M | 7.24M | 6.22M | 4.90M | 3.59M |
| Other Expenses | 367.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 68.15M | 72.94M | 72.75M | 67.67M | 57.04M | 47.77M | 45.86M | 42.53M | 31.34M | 24.78M | 25.30M |
| Cost & Expenses | 68.15M | 72.94M | 72.75M | 67.67M | 57.04M | 47.77M | 45.86M | 42.53M | 31.34M | 24.78M | 25.30M |
| Interest Income | 4.28M | 1.14M | 99.00K | 367.00K | 1.60M | 693.00K | 610.00K | 335.00K | 357.52K | 347.85K | 234.82K |
| Interest Expense | 49.00K | 605.00K | 548.00K | 271.00K | 27.00K | 102.00K | 197.00K | 89.00K | 216.00 | 853.00 | 8.29K |
| Depreciation & Amortization | 2.42M | 2.39M | 2.57M | 2.89M | 2.47M | 924.00K | 1.15M | 1.09M | 909.39K | 809.53K | 793.02K |
| EBITDA | -59.53M | 120.85M | -60.67M | -59.59M | -33.71M | -36.54M | -24.70M | -18.06M | -1.02M | -1.47M | 7.93M |
| EBITDA Ratio | -845.84% | 63.37% | -651.25% | -589.73% | -160.26% | -350.25% | -120.35% | -78.39% | -3.51% | 11.23% | 25.10% |
| Operating Income | -61.11M | 116.61M | -63.42M | -58.33M | -36.66M | -37.41M | -25.84M | -19.49M | -2.22M | 1.84M | 7.12M |
| Operating Income Ratio | -868.26% | 61.52% | -679.72% | -624.21% | -179.86% | -361.27% | -129.12% | -84.57% | -7.62% | 6.91% | 21.95% |
| Total Other Income/Expenses | -876.00K | 1.24M | -365.00K | -4.45M | 389.00K | 374.00K | 414.00K | 874.00K | 2.07M | -4.12M | 24.93K |
| Income Before Tax | -61.98M | 117.85M | -63.78M | -62.78M | -36.27M | -37.04M | -25.43M | -18.61M | -148.82K | -2.28M | 7.14M |
| Income Before Tax Ratio | -880.70% | 62.17% | -683.63% | -671.82% | -177.95% | -357.66% | -127.05% | -80.78% | -0.51% | -8.57% | 22.03% |
| Income Tax Expense | 0.00 | 605.00K | 2.00K | -11.00K | 17.00K | -374.00K | 197.00K | 89.00K | 216.00 | 853.00 | 0.00 |
| Net Income | -61.98M | 117.85M | -63.79M | -62.76M | -36.29M | -37.04M | -25.43M | -18.61M | -148.82K | -2.28M | 7.14M |
| Net Income Ratio | -880.70% | 62.17% | -683.65% | -671.70% | -178.03% | -357.66% | -127.05% | -80.78% | -0.51% | -8.57% | 22.03% |
| EPS | -1.89 | 3.63 | -2.06 | -2.51 | -1.69 | -1.75 | -1.22 | -0.91 | -0.01 | -0.15 | 0.37 |
| EPS Diluted | -1.89 | 3.54 | -2.06 | -2.51 | -1.69 | -1.75 | -1.22 | -0.91 | -0.01 | -0.15 | 0.37 |
| Weighted Avg Shares Out | 32.77M | 32.47M | 31.01M | 25.00M | 21.41M | 21.17M | 20.86M | 20.43M | 19.54M | 15.29M | 19.49M |
| Weighted Avg Shares Out (Dil) | 32.77M | 33.27M | 31.01M | 25.00M | 21.41M | 21.17M | 20.86M | 20.43M | 19.54M | 15.29M | 19.49M |
Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript
Molecular Partners AG (MOLN) Q4 2022 Earnings Call Transcript
Molecular Partners AG (MOLN) Q2 2022 Earnings Call Transcript
Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant
Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States
Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19
Molecular Partners to Present Data from Localized Immune Agonist (MP0317), T-cell Engager, and Peptide-MHC Immunotherapy Programs at AACR Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports